ThomasK, ChowK, KirbyRS: Acute urinary retention: A review of the aetiology and management. Prostate Cancer Prostatic Dis, 2004; 7:32–37.
2.
CurrowDC, AgarMR, ToTH: Adverse events in hospice and palliative care: A pilot study to determine feasibility of collection and baseline rates. J Palliat Med, 2011; 14:309–314.
3.
NegroCL, MuirGH: Chronic urinary retention in men: How we define it, and how does it affect treatment outcome. BJU Int, 2012; 110:1590–1594.
4.
UherR, RarmerA, HenigsbergN, et al.: Adverse reactions to antidepressants. Br J Psychiatry, 2009; 195:202–210.
5.
VerhammeK, MiriamC, SturkenboomM, et al.: Drug-induced urinary retention: Incidence, management and prevention. Drug Saf, 2008; 31:373.
JamesR, FrasureHE, MahajaST: Urinary catheterization may not adversely impact quality of life in multiple sclerosis patients. ISRN Neurol, 2014:167030.
8.
RosowCE, GomeryP, ChenTY, et al.: Reversal of opioid-induced bladder dysfunction by inravenous naloxone and methylnaltrexone. Clin Pharmacol Ther, 2007; 82:48–53.
9.
GartenL, BuhrerC: Reversal of morphine-induced urinary retention after methylnaltrexone. Arch Dis Child Fetal Neonatal Ed, 2012; 97:F151–F153.
10.
LenzeEJ: Reversal of SSRI-associated urinary retention with mirtazapine augmentation. J Clin Psychopharmacol, 2012; 32:434.
